Abstract:ABSTRACT Chronic hepatitis B virus (HBV) infections affect over 250 million people worldwide, and over 800,000 are expected to die yearly from complications including cirrhosis and primary hepatocellular carcinoma. While clinically available nucleoside analog-based antiviral therapies inhibit virus production, they cannot cure infections due to the persistence of covalently closed circular (cccDNA) in the nuclei of infected hepatocytes. Hence, the goals of future curative antiviral therapies for chronic hepatitis B are to either eliminate or permanently silence transcription from cccDNA. Novel antiviral approaches building on a better understanding of the mechanisms underlying transcriptional regulation and the stability of HBV cccDNA will be necessary to accomplish such goals. To advance our understanding of cccDNA biology, we have employed a CRISPR/Cas9-based system to produce extrachromosomal circular (ec) DNA from plasmid DNA integrated into the host genome originally developed by Moller et al. [Nucleic Acid Research 46:(22) e131, 2018]. We modified the enhanced green fluorescent protein (EGFP) reporter system to include portions of the HBV genome encoding wild-type and inactive hepatitis B virus X (HBx) proteins on ecDNA to mimic cccDNA. We demonstrated that expression of EGFP is inhibited by the SMC5/6 complex, as is cccDNA, and that HBx expression can reverse transcriptional silencing of ecDNA. Moreover, we demonstrated that ecDNA is lost during cell division. The system described in this report permits investigations on ecDNA and enables large-scale screening of compound libraries for small molecules targeting host factors involved in ecDNA and, by inference, cccDNA transcription, maintenance, and loss during cell division. IMPORTANCE Hepatitis B virus cccDNA is the key target for the necessary development of antiviral therapies aimed at curing chronic hepatitis B. The CRISPR-based system to produce covalently closed circular (cccDNA)-like extrachromosomal DNAs described in this report enables large-scale screens of chemical libraries to identify drug candidates with the potential to permanently inactivate cccDNA. Moreover, this approach permits investigations on unresolved problems as described in this report concerning cccDNA biology including mechanisms of SMC5/6-dependent transcriptional silencing and the contributions of the SMC5/6 complex to cccDNA stability in resting and dividing hepatocytes.

Tackling hepatitis B Virus with CRISPR/Cas9: advances, challenges, and delivery strategies

CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV

Applications of CRISPR/Cas as a Toolbox for Hepatitis B Virus Detection and Therapeutics

Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas

In vivo Delivery Tools for Clustered Regularly Interspaced Short Palindromic Repeat/Associated Protein 9-Mediated Inhibition of Hepatitis B Virus Infection: An Update

Targeting Hepatitis B Virus Cccdna by CRISPR/Cas9 Nuclease Efficiently Inhibits Viral Replication

CRISPR/Cas9 System with Dual Grnas Synergically Inhibit Hepatitis B Virus Replication

Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus

CRISPR/Cas9 as a New Antiviral Strategy for Treating Hepatitis Viral Infections

Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA

CRISPR-Cas13b-mediated suppression of hepatitis B virus replication and protein expression

The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer

Enhanced delivery of CRISPR/Cas9 system based on biomimetic nanoparticles for hepatitis B virus therapy

CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy

Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus

Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9

Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B

CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X

A CRISPR-based system to investigate HBV cccDNA biology

Inhibition of Hepatitis B Virus by AAV8-Derived CRISPR/SaCas9 Expressed From Liver-Specific Promoters

CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse